Mobile

A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellular...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003477-94

A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellular pertussis and inactivated poliovirus vaccine dTpa-IPV (Boostrix-Polio) when administered in healthy subjects aged 9-13 years, 5 years after previous booster vaccination with dTpa-IPV in the study 711866/001 (dTpa-IPV-001)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the incidence of grade 3 local reactions occurring during the 4-day (Day 0 - Day 3) follow-up period after administration of a booster dose of dTpa-IPV vaccine in healthy children and adolescents aged 9 to 13 years, 5 years after a previous booster dose of the same vaccine in the study 711866/001 (dTpa-IPV-001).

Critère d'inclusion

  • Booster immunisation against diphtheria, tetanus, pertussis and poliomyelitis diseases in children and adolescents

Liens